Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$17.49 -5.9%	$15.63	$12.72 ▼ $34.47	$3.18B	0.63	1.22 million shs	1.90 million shs
KYMR Kymera Therapeutics	$44.91 +0.0%	$40.03	$19.45 ▼ $53.27	$2.92B	2.18	620,900 shs	1.06 million shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
XERS Xeris Biopharma	$5.29 -2.8%	$4.77	$2.10 ▼ $6.07	$827.28M	0.66	2.06 million shs	1.75 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	-5.92%	+3.55%	+11.69%	+17.86%	-42.67%
KYMR Kymera Therapeutics	+0.02%	+3.41%	-4.37%	+79.50%	-0.20%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	+2.21%
XERS Xeris Biopharma	-2.76%	+10.90%	+21.61%	+29.66%	+113.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMVT Immunovant	1.3621 of 5 stars	3.4	0.0	0.0	0.0	2.2	1.7	0.0
KYMR Kymera Therapeutics	3.0938 of 5 stars	4.5	1.0	0.0	0.0	3.3	2.5	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	3.9403 of 5 stars	2.4	3.0	0.0	4.2	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.82	Moderate Buy	$36.30	107.55% Upside
KYMR Kymera Therapeutics	3.00	Buy	$59.11	31.62% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	18.15% Upside

Current Analyst Ratings Breakdown

Latest XERS, KYMR, IMVT, and MOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
6/3/2025	KYMR Kymera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $64.00
6/3/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$38.00 ➝ $60.00
6/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$49.00 ➝ $79.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
KYMR Kymera Therapeutics	$47.07M	62.13	N/A	N/A	$12.90 per share	3.48
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
XERS Xeris Biopharma	$222.55M	3.72	N/A	N/A	($0.20) per share	-26.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
XERS Xeris Biopharma	-$54.84M	-$0.30	N/A	N/A	N/A	-20.25%	N/A	-12.07%	8/6/2025 (Estimated)

Latest XERS, KYMR, IMVT, and MOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A
8/5/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	11.16	11.16
KYMR Kymera Therapeutics	N/A	8.49	8.49
MOR MorphoSys	4.98	1.38	1.38
XERS Xeris Biopharma	N/A	1.72	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
KYMR Kymera Therapeutics	N/A
MOR MorphoSys	18.38%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	1.80%
KYMR Kymera Therapeutics	16.01%
MOR MorphoSys	0.05%
XERS Xeris Biopharma	4.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
XERS Xeris Biopharma	290	156.39 million	149.25 million	Optionable

XERS, KYMR, IMVT, and MOR Headlines

Recent News About These Companies

Brown Advisory Inc. Has $630,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

July 15 at 4:13 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Trading 7.4% Higher - Time to Buy?

July 9, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Moderate Buy" from Analysts

June 28, 2025 | marketbeat.com

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

June 18, 2025 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying Activity

June 17, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 Shares

June 17, 2025 | insidertrades.com

Kevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

June 16, 2025 | marketbeat.com

Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug

June 4, 2025 | chicagobusiness.comC

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

June 3, 2025 | finance.yahoo.com

Xeris Announces Details for Analyst & Investor Day

May 20, 2025 | businesswire.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

May 9, 2025 | finance.yahoo.com

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 8, 2025 | businesswire.com

4XERS : Earnings Outlook For Xeris Biopharma Holdings

May 7, 2025 | benzinga.com

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 7, 2025 | seekingalpha.com

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | seekingalpha.com

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit

April 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS, KYMR, IMVT, and MOR Company Descriptions

Immunovant NASDAQ:IMVT

$17.49 -1.10 (-5.92%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$17.60 +0.11 (+0.63%)

As of 07/15/2025 07:38 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics NASDAQ:KYMR

$44.91 +0.01 (+0.02%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$44.90 0.00 (-0.01%)

As of 07/15/2025 07:50 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 07/14/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Xeris Biopharma NASDAQ:XERS

$5.29 -0.15 (-2.76%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$5.28 0.00 (-0.09%)

As of 07/15/2025 07:43 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time